PS.

NHS Branded Medicines Tranche Framework for London and South of England

NHS EnglandcontractFind a Tender ↗Ref ocds-h6vhtk-0445bc32014L0024active

Estimated value

—

goods

Awarded value

—

Suppliers

39

9 SME

Lots

3

39 awarded

Published

20 Aug 2024

Description

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024<br/>Offer reference number: CM/PHR/22/5689<br/>CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

Scope

Reference
CM/PHR/22/5689
Commercial tool
Standalone contract
Contract dates
31 Aug 2024 to 31 Aug 2026
Main category
goods
CPV classifications
33600000
Contract locations
UK

Award criteria

Criteria the buyer will use to evaluate bids.

NameDescriptionTypeWeighting
——price—

Submission & procedure

Procedure
Open procedure

Award details· 39 awards

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

—

Award date

—

Contract start

—

Contract end

—

Awarded to
SP
Sun Pharma UK Ltd
BI
Biogen
CH
Celltrion Healthcare United Kingdom Limited
AS
AstraZeneca
TA
Thornton and Ross Ltd
GU
GlaxoSmithKline UK Limited
NP
Novartis Pharmaceuticals UK Ltd
EL
Eli Lilly and Company Ltd
AP
Aventis Pharma t/a Sanofi
AL
ACCORD-UK LTD
MH
Manx Healthcare Ltd
SME
CP
Chugai Pharma UK Ltd
SME
NP
Napp Pharmaceuticals Ltd
DL
Dr.Reddy's Laboratories (UK) Limited
SME
GR
Gedeon Richter UK Ltd
SME
TU
Teva UK Limited
MS
Merck Sharpe and Dohme (UK) Limited
CH
Celltrion Healthcare United Kingdom Limited
JL
Janssen-Cilag Ltd
OP
Organon Pharmaceuticals UK Ltd
TA
Thornton and Ross Ltd
GU
GlaxoSmithKline UK Limited
TU
Takeda UK Ltd
PL
Pfizer Ltd
ZP
Zentiva Pharma UK Ltd
RP
Roche Products Ltd
EL
Eli Lilly and Company Ltd
AP
Aventis Pharma ltd t/a Sanofi
AL
ACCORD-UK LTD
OU
Orifarm UK
SME
GB
Galapagos Biotech Ltd
SME
DL
Dr.Reddy's Laboratories (UK) Limited
SME
LP
LEO Pharma
BC
BIOSIMILAR COLLABORATIONS IRELAND LIMITED
SME
SO
Sobi (Swedish Orphan Biovitrum Ltd)
SME
UP
UCB Pharma Ltd (primary)
BI
Biogen
CH
Celltrion Healthcare United Kingdom Limited
NP
NOVARTIS PHARMACEUTICALS UK LIMITED

Lots · 3 total

Divisions of the contract. Each lot can be awarded separately.

View all →
LotTitleEst. valueStatus
1CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1£129.9mcancelled
2CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2£644.0mcancelled
3CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3£58.3mcancelled